Hana Niebur, MD, assistant professor at the University of Nebraska Children’s Hospital and Medical Center, discusses non-infectious complications of primary immune deficiency. Lung disease is the most common…
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, reviews treatment options for acute myeloid leukemia (AML) patients. Dr. Krivoshik states that, while patients traditionally receive…
Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia…
Donald B. Kohn, MD, of the University of California, Los Angeles, discusses hematopoietic stem cell gene therapy for primary immune deficiencies. Up to 89% of patients receiving hematopoietic…
Alessia Cavazza, PhD, of Great Ormond Street Institute of Child Health (ICH) at University College London, discusses her research related to the potential of emerging gene-editing technologies, particularly…
This video includes information related to immunoglobulin therapy for primary immunodeficiencies. The AAAAI has developed 8 guiding principles for the effective use of IVIG for patients with primary…
In a retrospective study of patients with single/multilineage bone marrow failure presented at the Virtual Edition of the 25th European Hematology Association Annual Congress, the authors sought to…
Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park…
Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, describes acute myeloid leukemia (AML) and details how emerging targeted treatments are transforming the…
In this “Practice Pearls” roundtable organized by Pharmacy Times, expert panelists discuss acute myeloid leukemia (AML) diagnosis and the various factors affecting decision-making for specialists treating patients with…
